Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Bardelli

Showing results (241-250 of 259) with videos related to

Pageof 26
Sort By:
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Cancer Discovery|October 2, 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsEmiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, et al.
Cell|April 9, 2016
A Vulnerability of a Subset of Colon Cancers with Potential Clinical UtilityLoredana Vecchione, Valentina Gambino, Jonne Raaijmakers, et al.
Cancer Discovery|September 22, 2025
The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancerMarco Avolio, Simonetta M Leto, Francesco Sassi, et al.
Cancer Cell|July 11, 2018
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal CancerGiulia Siravegna, Luca Lazzari, Giovanni Crisafulli, et al.
Cancer Discovery|December 31, 2016
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaLipika Goyal, Supriya K Saha, Leah Y Liu, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Nature Communications|April 21, 2021
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZGiulia Della Chiara, Federica Gervasoni, Michaela Fakiola, et al.
Molecular Oncology|August 5, 2020
Towards a cancer mission in Horizon Europe: recommendationsAnton Berns, Ulrik Ringborg, Julio E Celis, et al.
Ebiomedicine|September 20, 2024
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancerAlexia Mirandola, Andrei Kudriavtsev, Catalina Isabel Cofre Muñoz, et al.
Pageof 26

Showing results (241-250 of 259) with videos related to

Sort By:
Pageof 26
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Cancer Discovery|October 2, 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsEmiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, et al.
Cell|April 9, 2016
A Vulnerability of a Subset of Colon Cancers with Potential Clinical UtilityLoredana Vecchione, Valentina Gambino, Jonne Raaijmakers, et al.
Cancer Discovery|September 22, 2025
The molecular and functional landscape of resistance to FOLFIRI chemotherapy in metastatic colorectal cancerMarco Avolio, Simonetta M Leto, Francesco Sassi, et al.
Cancer Cell|July 11, 2018
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal CancerGiulia Siravegna, Luca Lazzari, Giovanni Crisafulli, et al.
Cancer Discovery|December 31, 2016
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive CholangiocarcinomaLipika Goyal, Supriya K Saha, Leah Y Liu, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Nature Communications|April 21, 2021
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZGiulia Della Chiara, Federica Gervasoni, Michaela Fakiola, et al.
Molecular Oncology|August 5, 2020
Towards a cancer mission in Horizon Europe: recommendationsAnton Berns, Ulrik Ringborg, Julio E Celis, et al.
Ebiomedicine|September 20, 2024
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancerAlexia Mirandola, Andrei Kudriavtsev, Catalina Isabel Cofre Muñoz, et al.
Pageof 26